

Date: April 24, 2024

To, **BSE Ltd.** P.J. Towers, Dalal Street, Mumbai-400001

Scrip Code: 524444

Sub:- Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

and

Outcome of Board Meeting held on April 24, 2024.

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we would like to inform you that, Board of Directors of the Company in their Board Meeting held today i.e. April 24, 2024 at the Registered office of the company approved the acquisition/purchase of 80% stake in Revin Labs Private Limited, for consideration of Rs. 44.80 crores.

Currently, the Issued and Paid up capital of the Company is Rs. 4,00,00,000 divided into 40,00,000 equity shares of Rs. 10 each. Hence, the Company will be acquiring 32,00,000 equity shares of Rs. 10 each at the issue price of Rs. 140 each (including premium amount of Rs. 130/- per share)

It is to be further noted that the amongst 44.80 crore, 50% amount shall cash consideration and the remaining 50% amount shall be adjusted by issuing equity shares of Evexia Lifecare Limited to the individual shareholders of Revin Labs Private Limited, subject to requisite approvals.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above acquisition is given in Annexure enclosed herewith.

The Meeting started at 01:00 pm and concluded at 02:00 pm

Kindly take the same on your records and oblige.

Thanking You,

Yours faithfully,

For Evexia Lifecare Limited

JAYESHBHAI R. THAKKAR MANAGING DIRECTOR DIN: 01631093



Annexure A

Disclosure pursuant to Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr. No.	Details of events that need to be provided	Information of such event(s)
1.	Name of the target entity, details in brief such as size, turnover etc.	Revin Labs Private Limited
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	This is not a Related Party transaction. The Promoters/ Promoter Group doesn't have any interest in the entity being acquired
3.	Industry to which the entity being acquired belongs	Analytical Testing Services to Pharmaceuticals and aTesting of drugs in its Certified Laboratory
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Evexia's acquisition of a 80% stake in Revin Labs Private Limited signifies a strategic alignment aimed at capitalizing on synergistic opportunities for business advancement
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	crores):- within 3 months from the date of signing of Shareholders Agreement
		 Issuing Shares of Evexia Lifecare Limited to the individual shareholders of Revin Labs Private Limited (for remaining 50% of the amount i.e. Rs. 22.40 crores):- within 15 days from date of requisite approvals



		(Formerly Known as Kavit Industries Ltd.)
7.	Nature of consideration – whether cash consideration or share swap and details of the	50% amount (i.e. Rs. 22.4 crores) shall be cash consideration.
	same;	Balance 50% amount (i.e. Rs. 22.4 crores) shall be adjusted by issuing equity shares of Evexia Lifecare Limited to the individual shareholders of Revin Labs Private Limited. However, Separate Board Meeting shall be held for the above item.
8.	Cost of acquisition or the price at which the shares are acquired;	Rs.140 per equity share
9.	Percentage of shareholding/ control acquired and/or number of shares acquired;	80%
10.	Brief background about the entity acquired in terms of:	
	line of business acquired:	Testing of drugs
	products	NA
	date of incorporation:	July 09, 2018
	 history of last 3 years' turnover: 	(Rs. In Crores)
		2023-24 2022-23 2021-22 (provision al)
		16.57 10.63 10.37
		I
	Profit After Tax	(Rs. In Crores)
		2023-24 2022-23 2021-22 (provision al)
		3.90 1.41 1.39
	 country in which the acquired entity has presence: 	India